Furthermore, four (OSGIN1, AHR, IRF2BP2, and RASGEF1B) were shown to be strongly regulated upon LGZG therapy, which may play potential roles in NAFLD physiopathology (Figure 7, Table 1). Here, OSGIN1 is linked to metabolic dysfunction-associated steatotic liver disease.